Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
Go back to Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)| Alcon, Inc. (NYSE: ACL) | Delayed: 167.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $167.99 | 52 Week High | $170.64 | |||
| Open | $0.50 | 52 Week Low | $134.44 | |||
| Day High | $167.99 | P/E | N/A | |||
| Day Low | $167.99 | EPS | $0.00 | |||
| Volume | 12,500 | |||||
| NOVARTIS AG (NYSE: NVS) | Delayed: 158.86 +2.62 (1.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $156.24 | 52 Week High | $89.15 | |||
| Open | $156.17 | 52 Week Low | $69.84 | |||
| Day High | $159.72 | P/E | N/A | |||
| Day Low | $156.10 | EPS | $0.00 | |||
| Volume | 1,183,726 | |||||
